Dissolvable heart patch could spare patients from surgery
NCT ID NCT07529028
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a new device called Absnow II that closes a common heart hole (atrial septal defect) and then dissolves over time. About 236 people with a hole between 5 and 26 mm will get either the new device or a standard one. The goal is to see if the new device works just as well and is safe, potentially avoiding the need for lifelong implants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Absnow II absorbable atrial septal defect occluder (a device that closes a hole in the heart and then dissolves over time)
What this could lead to
If successful, this could offer a safer, less invasive way to close certain heart holes, with the device dissolving after the hole heals, potentially reducing long-term risks.
What could go wrong
This is an early-stage trial with only 236 participants, so results may not apply to everyone. The device might not close the hole as effectively or could cause complications like blood clots or device movement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL SEPTAL DEFECT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••